Toronto, ON – March 28, 2013 - Theralase
Technologies Inc. (TSXV: TLT) (“Theralase”) announced today that it has made
application to the TSX Venture Exchange for approval to extend the expiry date
of its outstanding common share purchase warrants.
Theralase has applied to have the expiry date of
the warrants amended from April 13, 2013 to April 13, 2017 for the 1,500,000 total
warrants issued on April 13, 2012. The exercise price of the warrants remains
unchanged at $0.38 per warrant, with the exception that the warrants will be
cancelled if they are not exercised within thirty (30) days from written notice
that the closing price of Theralase’s common
shares had been $0.75 or greater for 10 consecutive trading days.
About
Theralase Technologies Inc.:
Theralase Technologies Inc., founded in 1995, designs, develops,
manufactures and markets patented, superpulsed laser technology utilized in
biostimulation and biodestruction applications. Theralase technology is safe
and effective in treating pain, inflammation and for tissue regeneration of
neural muscular skeletal conditions and wound healing. Theralase is currently
developing proprietary Photo Dynamic Compounds (PDCs) that are able to target
and destroy cancers, bacteria and viruses when light activated by Theralase’s
proprietary and patented laser technology.
For further information please visit www.theralase.com
, regulatory filings may be viewed by visiting www.sedar.com.
This press release contains forward-looking statements, which reflect
the Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. The Company disclaims any obligation to
update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchanges) accepts
responsibility for the adequacy or accuracy of this release.
For More Information:
Roger Dumoulin-White
President & CEO
416-699-5273 ext. 225
Kristina Hachey
Chief Financial Officer
416-699-5273 ext. 224
Greg Bewsh
Director of Investor Relations
416-699-5273 ext. 258
No comments:
Post a Comment